Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Monday said the European Commission approved expanded use of its Spravato nasal spray for the rapid reduction of depressive symptoms in a psychiatric emergency for adults with major depressive disorder.
The drug maker said the approval covers Spravato, co-administered with oral antidepressant therapy, as an acute short-term treatment for the rapid reduction of depressive symptoms that, according to clinical judgment, constitute a psychiatric emergency.
The European Commission previously approved Spravato for adults with treatment-resistant major depressive disorder.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.